论文部分内容阅读
目的:探究针对类风湿关节炎患者的治疗中联合应用甲氨蝶呤及来氟米特的临床疗效以及安全性。方法:自2013年3月~2014年3月期间,选取我院收治类风湿关节炎共68例患者作为此次的研究对象,并随机将其分为对照组与研究组各34例,给予对照组柳氮硫氨嘧啶联合甲氨蝶呤的治疗措施,给予研究组甲氨蝶呤联合来氟米特的治疗措施,并对两组的临床效果进行对比评价。结果:研究组治疗后的总有效率为91.18%,不良反应的发生率为5.88%,疾病复发率为8.82%;对照组治疗后的总有效率为73.53%,不良反应的发生率为26.47%,疾病复发率为29.41%,且研究组各项临床指标显著优于对照组,组间对比差异显著具有统计学意义(P<0.05)。结论:针对类风湿关节炎患者的治疗中,联合应用甲氨蝶呤及来氟米特的治疗措施获得较为理想的临床效果,且基本复发率较低,安全性较高,值得在临床上普及应用。
Objective: To investigate the clinical efficacy and safety of combined methotrexate and leflunomide in the treatment of patients with rheumatoid arthritis. Methods: From March 2013 to March 2014, a total of 68 patients with rheumatoid arthritis admitted to our hospital were enrolled in this study. They were randomly divided into control group and study group, with 34 cases in each group. The group treated with methotrexate and methotrexate combined with methotrexate was given methotrexate combined with leflunomide in the study group. The clinical effects of the two groups were compared and evaluated. Results: The total effective rate of the study group was 91.18%, the incidence of adverse reactions was 5.88%, the disease recurrence rate was 8.82%; the total effective rate of the control group after treatment was 73.53%, the incidence of adverse reactions was 26.47% , The disease recurrence rate was 29.41%, and the clinical indicators of the study group was significantly better than the control group, the difference between the groups was statistically significant (P <0.05). Conclusion: The treatment of patients with rheumatoid arthritis combined with methotrexate and leflunomide treatment to obtain the ideal clinical effect, and the basic recurrence rate is low, high safety, it is worth popularizing in clinical application.